sniff results
“GLP-1”
93 total hits · 0 drugs · 0 companies · 0 diseases · 10 catalysts · 83 news
Drugs(0)
expand →
no drug names matched
🐶 Companies(0)
expand →
no companies matched
Catalysts(10)
expand →
Apr 17, 2026
grant
UNIVERSITY OF MICHIGAN AT ANN ARBOR — Remote Loading of Melanocortin and GLP-1 Peptides in Polymers for Treatment o...
→
Mar 23, 2026
grant
UNIVERSITY OF FLORIDA — Navigating the Uncertainties of Thyroid Cancer Risk in GLP-1RA Users
University of Florida
→
Mar 15, 2026
grant
MAYO CLINIC ROCHESTER — Real world impact of glucagon-like peptide receptor agonist (GLP-1 RA) use on...
Mayo Clinic
→
Feb 15, 2026
grant
UNIVERSITY OF CINCINNATI — GLP-1 Agonists for Preventing Alzheimer's Disease in Mild Cognitive Impairment
Metallomix Inc
→
Sep 18, 2025
grant
EMORY UNIVERSITY — From Evidence to Policy: Tailoring GLP-1RA Coverage for Optimal Health Outcomes
Emory University
→
Sep 15, 2025
grant
NEW YORK UNIVERSITY SCHOOL OF MEDICINE — “GLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): a multi...
New York University
→
Sep 10, 2025
grant
EMORY UNIVERSITY — Real-world utilization, effectiveness, and safety of GLP-1 receptor agonists ...
Emory University
→
COMPLETED
phase readout
NCT07194317: A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment
→
News(83)
expand →
- Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & LeeOne of Italy's large family-owned pharmaceutical companies is throwing its hat into the ring to compete with the GLP-1 giants in Europe. Menarini Group is gaining hold of the European rights to a G…endpoints · 2d ago
- Menarini signs $771M deal to take Gan & Lee GLP-1 to European marketItalian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of G…fiercebiotech · 2d ago
- Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical modelsEfficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on…biospace · 4d ago
- From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Apple